AP911A - Combinatin of aldose reductase inhibitor and a glycogen phosphorylase inhibitor. - Google Patents

Combinatin of aldose reductase inhibitor and a glycogen phosphorylase inhibitor. Download PDF

Info

Publication number: AP911A
Authority: AP; ARIPO
Prior art keywords: alkyl; mono; inhibitor; aldose reductase; glycogen phosphorylase
Prior art date: 1997-11-21

Application number

APAP/P/1998/001401A

Other languages

English (en)

Other versions

AP9801401A0 (en

Inventor

Banavara L Mylari

Denis Jay Hoover

Bernard Hulin

Judith Lee Treadway

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-11-21

Filing date

1998-11-19

Publication date

2000-12-07

1998-11-19 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

1998-12-31 Publication of AP9801401A0 publication Critical patent/AP9801401A0/xx

2000-12-07 Application granted granted Critical

2000-12-07 Publication of AP911A publication Critical patent/AP911A/en

Links

239000003288 aldose reductase inhibitor Substances 0.000 title abstract description 13
229940118148 Aldose reductase inhibitor Drugs 0.000 title description 7
ROJNYKZWTOHRNU-UHFFFAOYSA-N 2-chloro-4,5-difluoro-n-[[2-methoxy-5-(methylcarbamoylamino)phenyl]carbamoyl]benzamide Chemical compound CNC(=O)NC1=CC=C(OC)C(NC(=O)NC(=O)C=2C(=CC(F)=C(F)C=2)Cl)=C1 ROJNYKZWTOHRNU-UHFFFAOYSA-N 0.000 title description 5
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 22
238000011282 treatment Methods 0.000 abstract description 12
102000004877 Insulin Human genes 0.000 abstract description 11
108090001061 Insulin Proteins 0.000 abstract description 11
206010012601 diabetes mellitus Diseases 0.000 abstract description 11
229940125396 insulin Drugs 0.000 abstract description 11
102000007390 Glycogen Phosphorylase Human genes 0.000 abstract description 7
108010046163 Glycogen Phosphorylase Proteins 0.000 abstract description 7
229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 abstract description 6
239000003112 inhibitor Substances 0.000 abstract description 5
208000028867 ischemia Diseases 0.000 abstract description 5
239000000203 mixture Substances 0.000 abstract description 4
238000000034 method Methods 0.000 abstract description 3
230000000451 tissue damage Effects 0.000 abstract description 3
231100000827 tissue damage Toxicity 0.000 abstract description 3
125000000217 alkyl group Chemical group 0.000 description 29
-1 zopolrestat Chemical class 0.000 description 25
206010020772 Hypertension Diseases 0.000 description 16
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
239000008103 glucose Substances 0.000 description 10
125000005843 halogen group Chemical group 0.000 description 10
150000001875 compounds Chemical class 0.000 description 9
201000001320 Atherosclerosis Diseases 0.000 description 8
125000003545 alkoxy group Chemical group 0.000 description 8
230000034994 death Effects 0.000 description 8
231100000517 death Toxicity 0.000 description 8
230000002440 hepatic effect Effects 0.000 description 8
150000002632 lipids Chemical class 0.000 description 8
208000001072 type 2 diabetes mellitus Diseases 0.000 description 8
239000008280 blood Substances 0.000 description 7
210000004369 blood Anatomy 0.000 description 7
230000009229 glucose formation Effects 0.000 description 7
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
230000004116 glycogenolysis Effects 0.000 description 6
125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
201000010099 disease Diseases 0.000 description 5
208000035475 disorder Diseases 0.000 description 5
210000004185 liver Anatomy 0.000 description 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
208000010125 myocardial infarction Diseases 0.000 description 5
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 5
BCSVCWVQNOXFGL-UHFFFAOYSA-N 3,4-dihydro-4-oxo-3-((5-trifluoromethyl-2-benzothiazolyl)methyl)-1-phthalazine acetic acid Chemical compound O=C1C2=CC=CC=C2C(CC(=O)O)=NN1CC1=NC2=CC(C(F)(F)F)=CC=C2S1 BCSVCWVQNOXFGL-UHFFFAOYSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
208000024172 Cardiovascular disease Diseases 0.000 description 4
229920002527 Glycogen Polymers 0.000 description 4
208000031226 Hyperlipidaemia Diseases 0.000 description 4
125000004453 alkoxycarbonyl group Chemical group 0.000 description 4
229910052799 carbon Inorganic materials 0.000 description 4
230000000747 cardiac effect Effects 0.000 description 4
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 description 4
229940096919 glycogen Drugs 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
229950005346 zopolrestat Drugs 0.000 description 4
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 3
125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 3
208000007530 Essential hypertension Diseases 0.000 description 3
206010019280 Heart failures Diseases 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
206010041277 Sodium retention Diseases 0.000 description 3
239000003472 antidiabetic agent Substances 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
125000004093 cyano group Chemical group *C#N 0.000 description 3
230000000694 effects Effects 0.000 description 3
125000002541 furyl group Chemical group 0.000 description 3
229940126904 hypoglycaemic agent Drugs 0.000 description 3
230000002218 hypoglycaemic effect Effects 0.000 description 3
125000002883 imidazolyl group Chemical group 0.000 description 3
230000000302 ischemic effect Effects 0.000 description 3
125000001786 isothiazolyl group Chemical group 0.000 description 3
125000000842 isoxazolyl group Chemical group 0.000 description 3
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
125000002971 oxazolyl group Chemical group 0.000 description 3
125000003373 pyrazinyl group Chemical group 0.000 description 3
125000003226 pyrazolyl group Chemical group 0.000 description 3
125000002098 pyridazinyl group Chemical group 0.000 description 3
125000004076 pyridyl group Chemical group 0.000 description 3
125000000714 pyrimidinyl group Chemical group 0.000 description 3
125000000168 pyrrolyl group Chemical group 0.000 description 3
125000000335 thiazolyl group Chemical group 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
RIIVBOIBIOLLPO-UHFFFAOYSA-N 2-phthalazin-1-ylacetic acid Chemical compound C1=CC=C2C(CC(=O)O)=NN=CC2=C1 RIIVBOIBIOLLPO-UHFFFAOYSA-N 0.000 description 2
208000035150 Hypercholesterolemia Diseases 0.000 description 2
208000013016 Hypoglycemia Diseases 0.000 description 2
208000001647 Renal Insufficiency Diseases 0.000 description 2
229940100389 Sulfonylurea Drugs 0.000 description 2
208000007536 Thrombosis Diseases 0.000 description 2
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
125000003282 alkyl amino group Chemical group 0.000 description 2
210000000709 aorta Anatomy 0.000 description 2
210000001367 artery Anatomy 0.000 description 2
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
238000007675 cardiac surgery Methods 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
235000012000 cholesterol Nutrition 0.000 description 2
125000001153 fluoro group Chemical group F* 0.000 description 2
208000019622 heart disease Diseases 0.000 description 2
201000001421 hyperglycemia Diseases 0.000 description 2
201000006370 kidney failure Diseases 0.000 description 2
230000003902 lesion Effects 0.000 description 2
229920002521 macromolecule Polymers 0.000 description 2
125000002757 morpholinyl group Chemical group 0.000 description 2
208000037891 myocardial injury Diseases 0.000 description 2
125000004043 oxo group Chemical group O=* 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
125000004193 piperazinyl group Chemical group 0.000 description 2
125000003386 piperidinyl group Chemical group 0.000 description 2
230000002265 prevention Effects 0.000 description 2
125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 2
125000003072 pyrazolidinyl group Chemical group 0.000 description 2
125000002755 pyrazolinyl group Chemical group 0.000 description 2
125000000719 pyrrolidinyl group Chemical group 0.000 description 2
230000010410 reperfusion Effects 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
210000000329 smooth muscle myocyte Anatomy 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
210000005166 vasculature Anatomy 0.000 description 2
RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
VMJNTFXCTXAXTC-UHFFFAOYSA-N 2,2-difluoro-1,3-benzodioxole-5-carbonitrile Chemical group C1=C(C#N)C=C2OC(F)(F)OC2=C1 VMJNTFXCTXAXTC-UHFFFAOYSA-N 0.000 description 1
VFTOHJFKIJLYKN-UHFFFAOYSA-N 7-nitro-9h-fluoren-2-ol Chemical group [O-][N+](=O)C1=CC=C2C3=CC=C(O)C=C3CC2=C1 VFTOHJFKIJLYKN-UHFFFAOYSA-N 0.000 description 1
239000005541 ACE inhibitor Substances 0.000 description 1
PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
108010064733 Angiotensins Proteins 0.000 description 1
102000015427 Angiotensins Human genes 0.000 description 1
208000031104 Arterial Occlusive disease Diseases 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
229940123208 Biguanide Drugs 0.000 description 1
206010007559 Cardiac failure congestive Diseases 0.000 description 1
206010007572 Cardiac hypertrophy Diseases 0.000 description 1
208000006029 Cardiomegaly Diseases 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
206010010071 Coma Diseases 0.000 description 1
208000007342 Diabetic Nephropathies Diseases 0.000 description 1
208000032131 Diabetic Neuropathies Diseases 0.000 description 1
102000016942 Elastin Human genes 0.000 description 1
108010014258 Elastin Proteins 0.000 description 1
208000017701 Endocrine disease Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
208000002705 Glucose Intolerance Diseases 0.000 description 1
206010018429 Glucose tolerance impaired Diseases 0.000 description 1
206010053240 Glycogen storage disease type VI Diseases 0.000 description 1
206010060378 Hyperinsulinaemia Diseases 0.000 description 1
206010020880 Hypertrophy Diseases 0.000 description 1
229940122355 Insulin sensitizer Drugs 0.000 description 1
OWYWGLHRNBIFJP-UHFFFAOYSA-N Ipazine Chemical compound CCN(CC)C1=NC(Cl)=NC(NC(C)C)=N1 OWYWGLHRNBIFJP-UHFFFAOYSA-N 0.000 description 1
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
108010028554 LDL Cholesterol Proteins 0.000 description 1
208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
102000016611 Proteoglycans Human genes 0.000 description 1
108010067787 Proteoglycans Proteins 0.000 description 1
208000004531 Renal Artery Obstruction Diseases 0.000 description 1
206010038378 Renal artery stenosis Diseases 0.000 description 1
102100028255 Renin Human genes 0.000 description 1
108090000783 Renin Proteins 0.000 description 1
208000005392 Spasm Diseases 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
206010042434 Sudden death Diseases 0.000 description 1
LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
CKUAXEQHGKSLHN-UHFFFAOYSA-N [C].[N] Chemical compound [C].[N] CKUAXEQHGKSLHN-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
235000011054 acetic acid Nutrition 0.000 description 1
150000001243 acetic acids Chemical class 0.000 description 1
230000002411 adverse Effects 0.000 description 1
229960002478 aldosterone Drugs 0.000 description 1
125000005115 alkyl carbamoyl group Chemical group 0.000 description 1
239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
HXXFSFRBOHSIMQ-VFUOTHLCSA-N alpha-D-glucose 1-phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(O)=O)[C@H](O)[C@@H](O)[C@@H]1O HXXFSFRBOHSIMQ-VFUOTHLCSA-N 0.000 description 1
XKMRRTOUMJRJIA-UHFFFAOYSA-N ammonia nh3 Chemical compound N.N XKMRRTOUMJRJIA-UHFFFAOYSA-N 0.000 description 1
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
208000021328 arterial occlusion Diseases 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
229940097320 beta blocking agent Drugs 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
150000004283 biguanides Chemical class 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
229960001948 caffeine Drugs 0.000 description 1
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical group C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
239000007833 carbon precursor Substances 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
210000001627 cerebral artery Anatomy 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
208000033679 diabetic kidney disease Diseases 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
229920002549 elastin Polymers 0.000 description 1
230000008451 emotion Effects 0.000 description 1
230000001667 episodic effect Effects 0.000 description 1
125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
230000004110 gluconeogenesis Effects 0.000 description 1
150000002303 glucose derivatives Chemical class 0.000 description 1
230000010030 glucose lowering effect Effects 0.000 description 1
229950010772 glucose-1-phosphate Drugs 0.000 description 1
208000007345 glycogen storage disease Diseases 0.000 description 1
201000004510 glycogen storage disease VI Diseases 0.000 description 1
230000012010 growth Effects 0.000 description 1
125000001475 halogen functional group Chemical group 0.000 description 1
230000036541 health Effects 0.000 description 1
210000005003 heart tissue Anatomy 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
230000003451 hyperinsulinaemic effect Effects 0.000 description 1
201000008980 hyperinsulinism Diseases 0.000 description 1
208000006575 hypertriglyceridemia Diseases 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
230000007257 malfunction Effects 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
DOTMOQHOJINYBL-UHFFFAOYSA-N molecular nitrogen;molecular oxygen Chemical compound N#N.O=O DOTMOQHOJINYBL-UHFFFAOYSA-N 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
230000001338 necrotic effect Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
239000003538 oral antidiabetic agent Substances 0.000 description 1
229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000000813 peptide hormone Substances 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
208000028591 pheochromocytoma Diseases 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
230000000291 postprandial effect Effects 0.000 description 1
230000001292 preischemic effect Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000008569 process Effects 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
150000003212 purines Chemical class 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000008719 thickening Effects 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
230000014616 translation Effects 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
229940116269 uric acid Drugs 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
210000005167 vascular cell Anatomy 0.000 description 1
230000006444 vascular growth Effects 0.000 description 1
239000005526 vasoconstrictor agent Substances 0.000 description 1
230000002861 ventricular Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Superheterodyne Receivers (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Indole Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Noise Elimination (AREA)
Enzymes And Modification Thereof (AREA)

APAP/P/1998/001401A 1997-11-21 1998-11-19 Combinatin of aldose reductase inhibitor and a glycogen phosphorylase inhibitor. AP911A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US6636597P	1997-11-21	1997-11-21

Publications (2)

Publication Number	Publication Date
AP9801401A0 AP9801401A0 (en)	1998-12-31
AP911A true AP911A (en)	2000-12-07

Family

ID=22069038

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
APAP/P/1998/001401A AP911A (en)	1997-11-21	1998-11-19	Combinatin of aldose reductase inhibitor and a glycogen phosphorylase inhibitor.

Country Status (38)

Country	Link
EP (1)	EP1032424B9 (fr)
JP (1)	JP2002504478A (fr)
KR (2)	KR20010032304A (fr)
CN (1)	CN1279617A (fr)
AP (1)	AP911A (fr)
AR (1)	AR016423A1 (fr)
AT (1)	ATE205403T1 (fr)
AU (1)	AU733304B2 (fr)
BG (1)	BG104435A (fr)
BR (1)	BR9814698A (fr)
CA (1)	CA2310069A1 (fr)
DE (1)	DE69801680T2 (fr)
DK (1)	DK1032424T3 (fr)
DZ (1)	DZ2656A1 (fr)
EA (1)	EA002365B1 (fr)
ES (1)	ES2161548T3 (fr)
GR (1)	GR3037071T3 (fr)
GT (1)	GT199800166A (fr)
HR (1)	HRP20000327A2 (fr)
HU (1)	HUP0100272A3 (fr)
ID (1)	ID24524A (fr)
IL (1)	IL135713A0 (fr)
IS (1)	IS5453A (fr)
MA (1)	MA26568A1 (fr)
NO (1)	NO20002164L (fr)
OA (1)	OA11379A (fr)
PA (1)	PA8462301A1 (fr)
PE (1)	PE135399A1 (fr)
PL (1)	PL340643A1 (fr)
PT (1)	PT1032424E (fr)
SK (1)	SK7222000A3 (fr)
TN (1)	TNSN98211A1 (fr)
TR (1)	TR200001451T2 (fr)
UA (1)	UA57811C2 (fr)
UY (1)	UY25258A1 (fr)
WO (1)	WO1999026659A1 (fr)
YU (1)	YU30700A (fr)
ZA (1)	ZA9810636B (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2002536410A (ja) *	1999-02-12	2002-10-29	ノボノルディスクアクティーゼルスカブ	肥満の治療又は予防もしくは食欲の調節を目的とした薬学的組成物の製造におけるピロリジン誘導体の使用
EP1741445B1 (fr)	2000-01-21	2013-08-14	Novartis AG	Combinaisons à base d'inhibiteurs de DPP-IV et d'antidiabetiques
CO5271699A1 (es) *	2000-01-24	2003-04-30	Pfizer Prod Inc	Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
US6570013B2 (en)	2000-02-16	2003-05-27	Pfizer Inc	Salts of zopolrestat
US6395767B2 (en)	2000-03-10	2002-05-28	Bristol-Myers Squibb Company	Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
IL144507A0 (en) *	2000-07-31	2002-05-23	Pfizer Prod Inc	Use of glycogen phosphorylase inhibitors to inhibit tumor growth
WO2002098429A1 (fr) *	2001-06-07	2002-12-12	Pfizer Products Inc.	Formes salines du zopolrestat, a savoir ethanolamine, diethanolamine ou triethanolamine
GB0205175D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
GB0205162D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
GB0205165D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
GB0205166D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
GB0205170D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
GB0205176D0 (en)	2002-03-06	2002-04-17	Astrazeneca Ab	Chemical compounds
US7057046B2 (en)	2002-05-20	2006-06-06	Bristol-Myers Squibb Company	Lactam glycogen phosphorylase inhibitors and method of use
CA2392486A1 (fr)	2002-07-05	2002-12-08	Duchesnay Inc.	Forme posologique pharmaceutique portant une inscription pour les femmes enceintes
US7098235B2 (en)	2002-11-14	2006-08-29	Bristol-Myers Squibb Co.	Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
US7576121B2 (en)	2003-11-12	2009-08-18	Phenomix Corporation	Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7767828B2 (en)	2003-11-12	2010-08-03	Phenomix Corporation	Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7674913B2 (en)	2003-11-12	2010-03-09	Phenomix Corporation	Heterocyclic boronic acid compounds
US7317109B2 (en)	2003-11-12	2008-01-08	Phenomix Corporation	Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
WO2006017292A1 (fr)	2004-07-12	2006-02-16	Phenomix Corporation	Composes cyano contraints
WO2006055462A1 (fr)	2004-11-15	2006-05-26	Bristol-Myers Squibb Company	Derives 2-amino-4- tetraline fonctionnalisee et inhibiteurs de la glycogene phosphorylase associes
US7365061B2 (en)	2004-11-15	2008-04-29	Bristol-Myers Squibb Company	2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055435A1 (fr)	2004-11-15	2006-05-26	Bristol-Myers Squibb Company	Derives de 2-aminonaphtalene et inhibiteurs de la glycogene phosphorylase associes
WO2006053274A2 (fr)	2004-11-15	2006-05-18	Bristol-Myers Squibb Company	Derives de tetraline 2-amino-1-fonctionnalises et inhibiteurs correspondants de glycogene phosphorylase
EP2527337A1 (fr)	2005-04-14	2012-11-28	Bristol-Myers Squibb Company	Inhibiteurs de la 11-bêta hydroxystéroïde déshydrogénase de type I
US7825139B2 (en)	2005-05-25	2010-11-02	Forest Laboratories Holdings Limited (BM)	Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
CA2622608C (fr)	2005-09-14	2014-08-19	Takeda Pharmaceutical Company Limited	Administration d'inhibiteurs de dipeptidyl peptidase
EP2046753A2 (fr)	2006-07-06	2009-04-15	Brystol-Myers Squibb Company	Inhibiteurs de type i de la 11-bêta hydroxystéroïde déshydrogénase pyridone/hydroxypyridine
US7727978B2 (en)	2006-08-24	2010-06-01	Bristol-Myers Squibb Company	Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
JP2010524953A (ja)	2007-04-17	2010-07-22	ブリストル−マイヤーズスクイブカンパニー	縮合ヘテロ環１１−β−ヒドロキシステロイドデヒドロゲナーゼＩ型阻害剤
PE20090213A1 (es)	2007-05-04	2009-02-28	Bristol Myers Squibb Co	Agonistas del receptor acoplado a la proteina g gpr119 [6,5]-biciclicos
WO2008137435A1 (fr)	2007-05-04	2008-11-13	Bristol-Myers Squibb Company	Agonistes [6,6] and [6,7]-bicycliques du récepteur gpr 119 couplé à la protéine g
EA018709B1 (ru)	2007-07-17	2013-10-30	Бристол-Маерс Сквибб Компани	Пиридоновые агонисты сопряженного с g-белком рецептора gpr119
TW201006821A (en)	2008-07-16	2010-02-16	Bristol Myers Squibb Co	Pyridone and pyridazone analogues as GPR119 modulators
WO2011041293A1 (fr)	2009-09-30	2011-04-07	Takeda Pharmaceutical Company Limited	Dérivés pyrazolo [1, 5a] pyrimidines comme inhibiteurs de kinase 1 régulatrice de signal d'apoptose
SI2531501T1 (sl)	2010-02-03	2014-04-30	Takeda Pharmaceutical Company Limited	Inhibitorji kinaze-1, ki regulirajo signal apoptoze
MX2012011460A (es)	2010-04-08	2012-11-23	Squibb Bristol Myers Co	Analogos de pirimidinilpiperidiniloxipiridinona como moduladores de gpr119.
ES2559209T3 (es)	2010-04-14	2016-02-11	Bristol-Myers Squibb Company	Nuevos activadores de la glucocinasa y métodos de uso de los mismos
EA201270778A1 (ru)	2010-05-06	2013-04-30	Бристол-Майерс Сквибб Компани	Бициклические гетероарильные аналоги в качестве модуляторов рецептора gpr119
WO2011140161A1 (fr)	2010-05-06	2011-11-10	Bristol-Myers Squibb Company	Analogues de benzofuranyle en tant que modulateurs de gpr119
RU2013135224A (ru)	2011-01-20	2015-03-10	Бионевиа Фармасьютикалс Инк.	Композиции с модифицированным высвобождением эпалрестата или его производных и способы их использования
EP2850073B1 (fr)	2012-05-16	2017-07-19	Bristol-Myers Squibb Company	Analogues de pyrimidinylpipéridinyloxypyridone en tant que modulateurs de gpr119
US9580422B2 (en)	2013-10-22	2017-02-28	Bristol-Myers Squibb Company	Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
WO2018017910A1 (fr)	2016-07-22	2018-01-25	Bristol-Myers Squibb Company	Activateurs de glucokinase et leurs procédés d'utilisation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0624369A1 (fr) *	1993-05-10	1994-11-17	Pfizer Inc.	Méthode pour baisser le taux de lipides dans le sang
WO1996039384A1 (fr) *	1995-06-06	1996-12-12	Pfizer, Inc.	(indole-2-carbonyl-)-glycinamides substitues en n et leurs derives, servant d'inhibiteurs de la glycogene phosphorylase
WO1996039385A1 (fr) *	1995-06-06	1996-12-12	Pfizer Inc.	(indole-2-carbonyl-)-amides substitues en n et leurs derives, servant d'inhibiteurs de la glycogene phosphorylase

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4825448A (en) *	1986-08-07	1989-04-25	International Mobile Machines Corporation	Subscriber unit for wireless digital telephone system
DE3889326D1 (de) *	1988-05-27	1994-06-01	Itt Ind Gmbh Deutsche	Korrekturschaltung für ein digitales Quadratur-Signalpaar.

1998
- 1998-02-11 UA UA2000052869A patent/UA57811C2/uk unknown
- 1998-10-27 GT GT199800166A patent/GT199800166A/es unknown
- 1998-10-28 PA PA19988462301A patent/PA8462301A1/es unknown
- 1998-11-02 SK SK722-2000A patent/SK7222000A3/sk unknown
- 1998-11-02 BR BR9814698-0A patent/BR9814698A/pt not_active IP Right Cessation
- 1998-11-02 PT PT81300054T patent/PT1032424E/pt unknown
- 1998-11-02 AU AU95558/98A patent/AU733304B2/en not_active Ceased
- 1998-11-02 EP EP98949193A patent/EP1032424B9/fr not_active Expired - Lifetime
- 1998-11-02 CN CN98811329A patent/CN1279617A/zh active Pending
- 1998-11-02 ES ES98949193T patent/ES2161548T3/es not_active Expired - Lifetime
- 1998-11-02 DE DE69801680T patent/DE69801680T2/de not_active Expired - Fee Related
- 1998-11-02 JP JP2000521860A patent/JP2002504478A/ja active Pending
- 1998-11-02 EA EA200000433A patent/EA002365B1/ru not_active IP Right Cessation
- 1998-11-02 ID IDW20000958A patent/ID24524A/id unknown
- 1998-11-02 HU HU0100272A patent/HUP0100272A3/hu unknown
- 1998-11-02 AT AT98949193T patent/ATE205403T1/de not_active IP Right Cessation
- 1998-11-02 PL PL98340643A patent/PL340643A1/xx unknown
- 1998-11-02 KR KR1020007005514A patent/KR20010032304A/ko not_active Ceased
- 1998-11-02 TR TR2000/01451T patent/TR200001451T2/xx unknown
- 1998-11-02 YU YU30700A patent/YU30700A/sh unknown
- 1998-11-02 WO PCT/IB1998/001752 patent/WO1999026659A1/fr not_active Ceased
- 1998-11-02 HR HR20000327A patent/HRP20000327A2/hr not_active Application Discontinuation
- 1998-11-02 CA CA002310069A patent/CA2310069A1/fr not_active Abandoned
- 1998-11-02 IL IL13571398A patent/IL135713A0/xx unknown
- 1998-11-02 DK DK98949193T patent/DK1032424T3/da active
- 1998-11-16 PE PE1998001113A patent/PE135399A1/es not_active Application Discontinuation
- 1998-11-18 DZ DZ980266A patent/DZ2656A1/fr active
- 1998-11-18 TN TNTNSN98211A patent/TNSN98211A1/fr unknown
- 1998-11-19 AR ARP980105883A patent/AR016423A1/es not_active Application Discontinuation
- 1998-11-19 MA MA25356A patent/MA26568A1/fr unknown
- 1998-11-19 AP APAP/P/1998/001401A patent/AP911A/en active
- 1998-11-19 UY UY25258A patent/UY25258A1/es not_active Application Discontinuation
- 1998-11-20 ZA ZA9810636A patent/ZA9810636B/xx unknown
1999
- 1999-05-07 KR KR1020007013394A patent/KR100661214B1/ko not_active Expired - Fee Related
2000
- 2000-04-14 IS IS5453A patent/IS5453A/is unknown
- 2000-04-27 NO NO20002164A patent/NO20002164L/no not_active Application Discontinuation
- 2000-05-12 OA OA1200000137A patent/OA11379A/en unknown
- 2000-05-15 BG BG104435A patent/BG104435A/bg unknown
2001
- 2001-10-30 GR GR20010401943T patent/GR3037071T3/el not_active IP Right Cessation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0624369A1 (fr) *	1993-05-10	1994-11-17	Pfizer Inc.	Méthode pour baisser le taux de lipides dans le sang
WO1996039384A1 (fr) *	1995-06-06	1996-12-12	Pfizer, Inc.	(indole-2-carbonyl-)-glycinamides substitues en n et leurs derives, servant d'inhibiteurs de la glycogene phosphorylase
WO1996039385A1 (fr) *	1995-06-06	1996-12-12	Pfizer Inc.	(indole-2-carbonyl-)-amides substitues en n et leurs derives, servant d'inhibiteurs de la glycogene phosphorylase

Also Published As

Publication number	Publication date
OA11379A (en)	2004-01-28
UA57811C2 (uk)	2003-07-15
DE69801680D1 (de)	2001-10-18
IS5453A (is)	2000-04-14
NO20002164D0 (no)	2000-04-27
EA002365B1 (ru)	2002-04-25
KR20010032300A (ko)	2001-04-16
HRP20000327A2 (en)	2001-02-28
GR3037071T3 (en)	2002-01-31
PE135399A1 (es)	2000-01-15
UY25258A1 (es)	2000-12-29
ATE205403T1 (de)	2001-09-15
AP9801401A0 (en)	1998-12-31
EP1032424A1 (fr)	2000-09-06
KR20010032304A (ko)	2001-04-16
PA8462301A1 (es)	2000-05-24
WO1999026659A1 (fr)	1999-06-03
DE69801680T2 (de)	2002-02-07
ID24524A (id)	2000-07-20
KR100661214B1 (ko)	2006-12-26
ZA9810636B (en)	2000-05-22
GT199800166A (es)	2000-04-19
TR200001451T2 (tr)	2002-06-21
SK7222000A3 (en)	2001-09-11
PL340643A1 (en)	2001-02-12
TNSN98211A1 (fr)	2005-03-15
EP1032424B9 (fr)	2004-10-06
AR016423A1 (es)	2001-07-04
MA26568A1 (fr)	2004-12-20
CN1279617A (zh)	2001-01-10
EA200000433A1 (ru)	2000-12-25
CA2310069A1 (fr)	1999-06-03
BG104435A (bg)	2001-01-31
HUP0100272A2 (hu)	2001-06-28
JP2002504478A (ja)	2002-02-12
HUP0100272A3 (en)	2002-11-28
EP1032424B1 (fr)	2001-09-12
IL135713A0 (en)	2001-05-20
DZ2656A1 (fr)	2003-03-22
BR9814698A (pt)	2000-10-03
DK1032424T3 (da)	2001-11-19
YU30700A (sh)	2002-12-10
AU733304B2 (en)	2001-05-10
ES2161548T3 (es)	2001-12-01
AU9555898A (en)	1999-06-15
NO20002164L (no)	2000-07-19
PT1032424E (pt)	2001-12-28

Publication	Publication Date	Title
AP911A (en)	2000-12-07	Combinatin of aldose reductase inhibitor and a glycogen phosphorylase inhibitor.
AU706628B2 (en)	1999-06-17	Treatment of arteriosclerosis and xanthoma
US7166625B2 (en)	2007-01-23	Method for treating fibrotic diseases and other indications
US20030027820A1 (en)	2003-02-06	Method for treating fibrotic diseases or other indications V
ZA200608886B (en)	2008-06-25	Indolyl derivatives as liver-X-receptor modulators
EA015169B1 (ru)	2011-06-30	Применение ингибиторов дипептидилпептидазы
JP2010248205A (ja)	2010-11-04	強皮症の治療のためのベンザゾール誘導体
CN1771040B (zh)	2010-06-16	糖尿病治疗药
CA2448294A1 (fr)	2002-12-05	Methode de traitement de maladies fibreuses ou d'autres indications
RU2448093C2 (ru)	2012-04-20	Производные пиридина для лечения метаболических нарушений, связанных с устойчивостью к действию инсулина или гипергликемией
US20070043016A1 (en)	2007-02-22	Method of treating fibrotic diseases or other indications with imidazolium agents
AU2002241670B2 (en)	2006-08-17	Method for treating glaucoma IB
CA2448449A1 (fr)	2002-11-28	Traitement de fibrose renale
JP2000086629A (ja)	2000-03-28	新規な酸化窒素放出化合物
EP3993784A1 (fr)	2022-05-11	Procédés de polythérapie, compositions et kits
KR20010108387A (ko)	2001-12-07	당뇨병 치료제
CA2511735C (fr)	2011-09-20	Traitement de l'insuffisance renale a l'aide de levosimendan, de son metabolite ou de ses sels
TW202308611A (zh)	2023-03-01	包含１－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－甲酸之醫藥組成物
WO2006132196A1 (fr)	2006-12-14	PRODUIT PHARMACEUTIQUE ORIGINAL COMPRENANT UN AGONISTE β3
WO2002072098A1 (fr)	2002-09-19	Methode de traitement
CA2417883A1 (fr)	2002-02-14	Composition pharmaceutique comprenant de la metformine et un derive de type 5-phenoxyalkyle-2,4-thiazolidinedione
Bell	2001	Drugs for cardiovascular risk reduction in the diabetic patient
EP1864663A1 (fr)	2007-12-12	Agent prophylactique et/ou thérapeutique pour le traitement de la polyarthrite rhumatoïde
WO2010047369A1 (fr)	2010-04-29	Agent destiné au traitement de la néphropathie diabétique
MXPA96002577A (en)	1998-01-01	Treatment of arterioesclerosis and xant